(2011). HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry. Retrovirology, 8(1), 89. https://doi.org/10.1186/1742-4690-8-89
Chicago Style (17th ed.) Citation"HIV-1 Predisposed to Acquiring Resistance to Maraviroc (MVC) and Other CCR5 Antagonists in Vitro Has an Inherent, Low-level Ability to Utilize MVC-bound CCR5 for Entry." Retrovirology 8, no. 1 (2011): 89. https://doi.org/10.1186/1742-4690-8-89.
MLA (9th ed.) Citation"HIV-1 Predisposed to Acquiring Resistance to Maraviroc (MVC) and Other CCR5 Antagonists in Vitro Has an Inherent, Low-level Ability to Utilize MVC-bound CCR5 for Entry." Retrovirology, vol. 8, no. 1, 2011, p. 89, https://doi.org/10.1186/1742-4690-8-89.
